Dublin, Nov. 4, 2013 (GLOBE NEWSWIRE) -- Research and Markets (http://www.researchandmarkets.com/research/3lndkv/european_nuclear)
has announced the addition of the
"European Nuclear Medicine/Radiopharmaceuticals & Stable
Isotopes Market - Trends & Forecast to 2017" report to
their offering.
The European radioisotopes market was valued at $1.1 billion in
2012 and is poised to reach $1.6 billion in 2017 at a CAGR of
6.8%.
A study conducted by Organization for Economic Co-operation and
Development (OECD) estimates that Tc-99m diagnostic procedures are
expected to increase by 15% to 20% in mature markets such as
Europe, and other developed regions between 2010 and 2030.
Radiopharmaceuticals in neurological applications such as
Alzheimer's disease, Parkinson's disease, and dementia are also
being preferred by practitioners besides conventional treatment.
Further, upcoming radioisotopes such as Ra-223 (Alpharadin) and
Ga-68 possess huge potential for clinical applications. The
scheduled shutdown of the NRU reactor in 2016 and OSIRIS in France
in 2018 is, however, a major threat for manufacturers.
The therapy market is predominantly driven by its oncologic
applications. Since conventional treatment procedures of cancer,
surgery and chemotherapy have significant side effects,
radioisotopes are being preferred by medical practitioners due to
minimum or no side effects. The radiopharmaceutical therapy market
is expected to grow significantly with the launch of the
much-desired Alpharadin (Ra-223) in the near future. This isotope
has tremendous potential to take up market share of beta emitters
and brachytherapy.
The radioisotope and stable isotope markets have been segmented
according to the type of isotope, and applications. Both of these
markets are broken down into segments and sub-segments, providing
exhaustive value analysis for the years 2010, 2011, 2012, and
forecast to 2017. Each market is comprehensively analyzed at a
granular level by geography (North America, Europe, Asia, and Rest
of the World) to provide in-depth information on the European
scenario.
Key Topics Covered:
1 Key Take-Aways
2 Executive Summary
3 Market Overview
4 European Radiopharmaceuticals Market, By Isotope
5 European Radiopharmaceuticals Market,By
Application/Indication
6 European Enriched Stable Isotopes Market
7 Geographic Analysis
8 Competitive Landscape
9 Company Profiles
Companies Mentioned
- Bracco Imaging
- Cambridge Isotope Laboratories
- Cardinal Health
- Covidien
- Eczacibasi-Monrol
- Fujifilm Holdings
- Ge Healthcare (Subsidiary Of General Electric Company)
- Iba Group
- Isotec
- Lantheus Medical Imaging
- Nordion
- Ntp Radioisotopes
- Petnet Solutions
- Rotem Industries
- Taiyo Nippon Sanso Corporation
- Urenco Limited
For more information visit http://www.researchandmarkets.com/research/3lndkv/european_nuclear
About Research and Markets
Research and Markets is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
Research and Markets
Laura Wood, Senior Manager.
press@researchandmarkets.com
U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716
Sector:
Pharmaceuticals